|
1
|
Brodeur GM: Neuroblastoma: Biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216.
2003.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pinto NR, Applebaum MA, Volchenboum SL,
Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F,
Schleiermacher G, Park JR, et al: Advances in risk classification
and treatment strategies for neuroblastoma. J Clin Oncol.
33:3008–3017. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Morgenstern DA, Potschger U, Moreno L,
Papadakis V, Owens C, Ash S, Pasqualini C, Luksch R, Garaventa A,
Canete A, et al: Risk stratification of high-risk metastatic
neuroblastoma: A report from the HR-NBL-1/SIOPEN study. Pediatr
Blood Cancer. 65(e27363)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Smith V and Foster J: High-risk
neuroblastoma treatment review. Children (Basel).
5(114)2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
MacFarland S and Bagatell R: Advances in
neuroblastoma therapy. Curr Opin Pediatr. 31:14–20. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tolbert VP and Matthay KK: Neuroblastoma:
Clinical and biological approach to risk stratification and
treatment. Cell Tissue Res. 372:195–209. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Uemura S, Ishida T, Thwin KKM, Yamamoto N,
Tamura A, Kishimoto K, Hasegawa D, Kosaka Y, Nino N, Lin KS, et al:
Dynamics of minimal residual disease in neuroblastoma patients.
Front Oncol. 9(455)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
London WB, Castel V, Monclair T, Ambros
PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL,
Iehara T and Matthay KK: Clinical and biologic features predictive
of survival after relapse of neuroblastoma: A report from the
International Neuroblastoma Risk Group project. J Clin Oncol.
29:3286–3292. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Riley RD: A systematic review of molecular
and biological tumor markers in neuroblastoma. Clin Cancer Res.
10:4–12. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Brodeur GM, Seeger RC, Barrett A, Berthold
F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M,
Freeman AI, et al: International criteria for diagnosis, staging,
and response to treatment in patients with neuroblastoma. J Clin
Oncol. 6:1874–1881. 1988.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Brodeur GM, Pritchard J, Berthold F,
Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE,
Favrot M, Hedborg F, et al: Revisions of the international criteria
for neuroblastoma diagnosis, staging, and response to treatment. J
Clin Oncol. 11:1466–1477. 1993.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Simon T, Hero B, Hunneman DH and Berthold
F: Tumour markers are poor predictors for relapse or progression in
neuroblastoma. Eur J Cancer. 39:1899–1903. 2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cohn SL, Pearson ADJ, London WB, Monclair
T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et
al: The international neuroblastoma risk group (INRG)
classification system: An INRG task force report. J Clin Oncol.
27:289–297. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Park JR, Bagatell R, Cohn SL, Pearson AD,
Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K,
Nuchtern JG, et al: Revisions to the international neuroblastoma
response criteria: A consensus statement from the national cancer
institute clinical trials planning meeting. J Clin Oncol.
35:2580–2587. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bozzi F, Gambirasio F, Luksch R, Collini
P, Brando B and Fossati-Bellani F: Detecting
CD56+/NB84+/CD45-immunophenotype
in the bone marrow of patients with metastatic neuroblastoma using
flow cytometry. Anticancer Res. 26:3281–3287. 2006.PubMed/NCBI
|
|
18
|
Popov A, Druy A, Shorikov E, Verzhbitskaya
T, Solodovnikov A, Saveliev L, Tytgat GAM, Tsaur G and Fechina L:
Prognostic value of initial bone marrow disease detection by
multiparameter flow cytometry in children with neuroblastoma. J
Cancer Res Clin Oncol. 145:535–542. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Stutterheim J, Ichou FA, den Ouden E,
Versteeg R, Caron HN, Tytgat GA and van der Schoot CE: Methylated
RASSF1a is the first specific DNA marker for minimal residual
disease testing in neuroblastoma. Clin Cancer Res. 18:808–814.
2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Beiske K, Ambros PF, Burchill SA, Cheung
IY and Swerts K: Detecting minimal residual disease in
neuroblastoma patients-the present state of the art. Cancer Lett.
228:229–240. 2005.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Brownhill SC and Burchill SA: PCR-based
amplification of circulating RNAs as prognostic and predictive
biomarkers-Focus on neuroblastoma. Pract Lab Med. 7:41–44.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Burchill SA, Bradbury FM, Smith B, Lewis
IJ and Selby P: Neuroblastoma cell detection by reverse
transcriptase-polymerase chain reaction (RT-PCR) for tyrosine
hydroxylase mRNA. Int J Cancer. 57:671–675. 1994.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Viprey VF, Corrias MV, Kågedal B, Oltra S,
Swerts K, Vicha A, Ladenstein R and Burchill SA: Standardisation of
operating procedures for the detection of minimal disease by
QRT-PCR in children with neuroblastoma: Quality assurance on behalf
of SIOPEN-R-NET. Eur J Cancer. 43:341–350. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Stutterheim J, Gerritsen A,
Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM,
Bierings M, Berthold F, Versteeg R, et al: PHOX2B is a novel and
specific marker for minimal residual disease testing in
neuroblastoma. J Clin Oncol. 26:5443–5449. 2008.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Stutterheim J, Zappeij-Kannegieter L,
Versteeg R, Caron HN, van der Schoot CE and Tytgat GAM: The
prognostic value of fast molecular response of marrow disease in
patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer.
47:1193–1202. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Viprey VF, Gregory WM, Corrias MV,
Tchirkov A, Swerts K, Vicha A, Dallorso S, Brock P, Luksch R,
Valteau-Couanet D, et al: Neuroblastoma mRNAs predict outcome in
children with stage 4 neuroblastoma: A European HR-NBL1/SIOPEN
study. J Clin Oncol. 32:1074–1083. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cheung NK, Ostrovnaya I, Kuk D and Cheung
IY: Bone marrow minimal residual disease was an early response
marker and a consistent independent predictor of survival after
anti-GD2 immunotherapy. J Clin Oncol. 33:755–763. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Marachelian A, Villablanca JG, Liu CW, Liu
B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R,
et al: Expression of five neuroblastoma genes in bone marrow or
blood of patients with relapsed/refractory neuroblastoma provides a
new biomarker for disease and prognosis. Clin Cancer Res.
23:5374–5383. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Akobeng AK: Understanding diagnostic tests
3: Receiver operating characteristic curves. Acta Paediatr.
96:644–647. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hartomo TB, Kozaki A, Hasegawa D, Van
Huyen Pham T, Yamamoto N, Saitoh A, Ishida T, Kawasaki K, Kosaka Y,
Ohashi H, et al: Minimal residual disease monitoring in
neuroblastoma patients based on the expression of a set of
real-time RT-PCR markers in tumor-initiating cells. Oncol Rep.
29:1629–1636. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hirase S, Saitoh A, Hartomo TB, Kozaki A,
Yanai T, Hasegawa D, Kawasaki K, Kosaka Y, Matsuo M, Yamamoto N, et
al: Early detection of tumor relapse/regrowth by consecutive
minimal residual disease monitoring in high-risk neuroblastoma
patients. Oncol Lett. 12:1119–1123. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Thwin KKM, Ishida T, Uemura S, Yamamoto N,
Lin KS, Tamura A, Kozaki A, Saito A, Kishimoto K, Mori T, et al:
Level of seven neuroblastoma-associated mRNAs detected by droplet
digital PCR is associated with tumor relapse/regrowth of high-risk
neuroblastoma patients. J Mol Diagn. 22:236–246. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Weinstein JL, Katzenstein HM and Cohn SL:
Advances in the diagnosis and treatment of neuroblastoma.
Oncologist. 8:278–292. 2003.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Burchill SA, Beiske K, Shimada H, Ambros
PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR and Berthold F:
Recommendations for the standardization of bone marrow disease
assessment and reporting in children with neuroblastoma on behalf
of the International Neuroblastoma Response Criteria Bone Marrow
Working Group. Cancer. 123:1095–1105. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bustin SA, Benes V, Garson JA, Hellemans
J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL,
et al: The MIQE guidelines: Minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Huggett JF, Foy CA, Benes V, Emslie K,
Garson JA, Haynes R, Hellemans J, Kubista M, Mueller RD, Nolan T,
et al: The digital MIQE guidelines: Minimum information for
publication of quantitative digital PCR experiments. Clin Chem.
59:892–902. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Schober P, Boer C and Schwarte LA:
Correlation coefficients. Anesth Analg. 126:1763–1768.
2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Moroz V, Machin D, Hero B, Ladenstein R,
Berthold F, Kao P, Obeng Y, Pearson ADJ, Cohn SL and London WB: The
prognostic strength of serum LDH and serum ferritin in children
with neuroblastoma: A report from the International Neuroblastoma
Risk Group (INRG) project. Pediatr Blood Cancer.
67(e28359)2020.PubMed/NCBI View Article : Google Scholar
|
